+关注
07gt
暂无个人介绍
IP属地：未知
12
关注
1
粉丝
0
主题
0
勋章
主贴
热门
07gt
2021-12-07
Nice
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4100934647201050","uuid":"4100934647201050","gmtCreate":1637832609199,"gmtModify":1638897116320,"name":"07gt","pinyin":"07gt","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6493987bc2c1982a3237088aa05803c9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":12,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.05.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"60.63%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606272142,"gmtCreate":1638889246502,"gmtModify":1638890681078,"author":{"id":"4100934647201050","authorId":"4100934647201050","name":"07gt","avatar":"https://static.tigerbbs.com/6493987bc2c1982a3237088aa05803c9","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100934647201050","idStr":"4100934647201050"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606272142","repostId":"1168326906","repostType":2,"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":606272142,"gmtCreate":1638889246502,"gmtModify":1638890681078,"author":{"id":"4100934647201050","authorId":"4100934647201050","name":"07gt","avatar":"https://static.tigerbbs.com/6493987bc2c1982a3237088aa05803c9","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100934647201050","idStr":"4100934647201050"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606272142","repostId":"1168326906","repostType":2,"repost":{"id":"1168326906","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638878102,"share":"https://www.laohu8.com/m/news/1168326906?lang=&edition=full","pubTime":"2021-12-07 19:55","market":"us","language":"en","title":"AstraZeneca to Work with Ionis on Eplontersen Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1168326906","media":"Dow Jones","summary":"AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly de","content":"<p></p>\n<p>AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly develop and commercialize the Californian biotechnology company's antisense drug Eplontersen.</p>\n<p>The companies will jointly develop and commercialize the drug in the U.S., while AstraZeneca will develop and commercialize Eplontersen in the rest of the world, except for Latin America, it said.</p>\n<p>The pharmaceutical company will pay Ionis $200 million up front and additional conditional payments of up to $485 million after regulatory approvals. It will also pay up to $2.9 billion of sales-related milestones, and royalties in the range of a low double-digit to a mid-twenties percentage, depending on the region.</p>\n<p>Eplontersen, which is currently in phase 3 clinical trials, treats amyloid transthyretin cardiomyopathy, or ATTR-CM--a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years of diagnosis. It also treats amyloid transthyretin polyneuropathy, or ATTR-PN, a disease causing peripheral nerve damage with motor disability within five years of diagnosis, and is generally fatal within a decade if untreated.</p>\n<p>Hereditary ATTR-PN treatment is likely to be the first regulatory approval for Eplontersen, with the potential to file a new drug application with the U.S. Food and Drug Administration by the end of 2022.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to Work with Ionis on Eplontersen Drug </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to Work with Ionis on Eplontersen Drug \n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-07 19:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p>AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly develop and commercialize the Californian biotechnology company's antisense drug Eplontersen.</p>\n<p>The companies will jointly develop and commercialize the drug in the U.S., while AstraZeneca will develop and commercialize Eplontersen in the rest of the world, except for Latin America, it said.</p>\n<p>The pharmaceutical company will pay Ionis $200 million up front and additional conditional payments of up to $485 million after regulatory approvals. It will also pay up to $2.9 billion of sales-related milestones, and royalties in the range of a low double-digit to a mid-twenties percentage, depending on the region.</p>\n<p>Eplontersen, which is currently in phase 3 clinical trials, treats amyloid transthyretin cardiomyopathy, or ATTR-CM--a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years of diagnosis. It also treats amyloid transthyretin polyneuropathy, or ATTR-PN, a disease causing peripheral nerve damage with motor disability within five years of diagnosis, and is generally fatal within a decade if untreated.</p>\n<p>Hereditary ATTR-PN treatment is likely to be the first regulatory approval for Eplontersen, with the potential to file a new drug application with the U.S. Food and Drug Administration by the end of 2022.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168326906","content_text":"AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly develop and commercialize the Californian biotechnology company's antisense drug Eplontersen.\nThe companies will jointly develop and commercialize the drug in the U.S., while AstraZeneca will develop and commercialize Eplontersen in the rest of the world, except for Latin America, it said.\nThe pharmaceutical company will pay Ionis $200 million up front and additional conditional payments of up to $485 million after regulatory approvals. It will also pay up to $2.9 billion of sales-related milestones, and royalties in the range of a low double-digit to a mid-twenties percentage, depending on the region.\nEplontersen, which is currently in phase 3 clinical trials, treats amyloid transthyretin cardiomyopathy, or ATTR-CM--a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years of diagnosis. It also treats amyloid transthyretin polyneuropathy, or ATTR-PN, a disease causing peripheral nerve damage with motor disability within five years of diagnosis, and is generally fatal within a decade if untreated.\nHereditary ATTR-PN treatment is likely to be the first regulatory approval for Eplontersen, with the potential to file a new drug application with the U.S. Food and Drug Administration by the end of 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
